CYPB - Sector: Healthcare --- Industry: Biotechnology

[setravis]

Profile:  



Cypress Bioscience, Inc.
4350 Executive Drive
Suite 325
San Diego, CA 92121
United States - Map
Phone: 858-452-2323
Fax: 858-452-1222
Web Site: http://www.cypressbio.com

DETAILS  
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 37


BUSINESS SUMMARY  
Cypress Bioscience, Inc. develops and commercializes pharmaceutical products and personalized medicine laboratory services to rheumatologists in the United States. The company is developing milnacipran, norepinephrine serotonin reuptake inhibitor for fibromyalgia syndrome. The milnacipran is a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine. It has collaboration/license agreements with Collegium Pharmaceutical, Inc.; Forest Laboratories, Inc.; and Pierre Fabre. The company was founded in 1981 and is based in San Diego, California.

[setravis]

Above the 50-day...
Target $14-22, stop $6. Above the 50-day. Cypress Bioscience - products & , Inc. develops and commercializes pharmaceutical products and personalized medicine laboratory services to rheumatologists in the United States.

52wk Range: 4.90 - 10.29
Volume: 11,707,800
Avg Vol (3m): 721,656

Technicals
Close Above the 13-day MA
Most Actives
Percentage Gainer

Last Price Quote is:
32.87%above 13-day MA
49.55%above 50-day MA
RS Rating: 95 

Fundamentals
Key Data:
Market Cap (M): $278.06 
P/E Ratio: 193.01 
PEG Ratio: N/A 
Next Earnings: 03/16/2009
Last Analyst Rating: Buy

[setravis]

some pre-market activity...

Cypress Bioscience, Inc.(NasdaqGM: CYPB)
Pre-Market Real-Time: 3.45  0.95 (38.00%) 8:42AM EDT